From December 5 to 6, 2025, the inaugural Academic Annual Conference of the Vascular Surgery Branch of the National Health Industry Enterprise Management Association, together with the 2025 Academic Symposium on New Advances in the Diagnosis and Treatment of Diabetic Foot, was grandly held in Beijing. Co-organized by the Zhongguancun Precision Medicine Foundation and other institutions, the conference brought together top experts and scholars from various disciplines—including vascular surgery, wound repair, and endocrinology—providing a platform for them to discuss the cutting-edge developments in their fields. At this conference, Mr. Xu Songshan, Chairman of our company, was appointed as a director of the Vascular Surgery Branch of the National Health Industry Enterprise Management Association, thanks to his profound industry background. As a technology-driven enterprise dedicated to biomedical innovation, NORTHLAND will, from an even higher vantage point, join forces with leading national experts to jointly promote the vigorous development of vascular surgery in China.

At the special session on arterial ischemic disease, Professor Cui Shijun from Xuanwu Hospital of Capital Medical University delivered an outstanding presentation titled “Application of Hepatocyte Growth Factor in Lower Limb Ischemic Diseases.” Professor Cui provided an in-depth explanation of the key mechanisms by which hepatocyte growth factor (HGF) promotes angiogenesis and improves blood circulation, while also demonstrating its effectiveness in enhancing tissue perfusion. The presentation highlighted the pivotal data from the Phase III clinical trial of Donaperminogene Seltoplasmid Injection. The results showed that Donaperminogene Seltoplasmid Injection demonstrated promising outcomes in alleviating symptoms of lower limb ischemia and accelerating wound healing, offering new hope for limb preservation, particularly for patients with severe lower limb ischemia (CLI) and diabetic foot.

  At the main venue of the conference, Professor Gu Yongquan, the incoming chairman of the Organ Regeneration and Regenerative Medicine Branch of the Chinese Medical Association and vice president of the first Vascular Surgery Physicians Branch of the Chinese Physicians Association, delivered a keynote speech titled “New Technological Applications in the Treatment of Ischemic Wounds of the Lower Limbs.” He pointed out that both domestically and internationally, groundbreaking achievements have been made in the treatment of lower-limb ischemia complicated by diabetes, and the application prospects for biotechnology drugs are immensely promising. Professor Gu specifically highlighted that the Phase I and Phase II clinical trials of Donaperminogene Seltoplasmid Ingection, led by him, have also yielded remarkable results. He fully endorsed the clinical trial findings and clinical application value of Donaperminogene Seltoplasmid Ingection, while also underscoring the promising potential of innovative gene therapies in the treatment of lower-limb ischemia, particularly diabetic foot, in China.

NORTHLAND will continue to leverage scientific research and innovation as its driving force, accelerate the commercial preparation of Donaperminogene Seltoplasmid Injection, and soon bring good news to the many patients suffering from lower-limb ischemia, collectively contributing solid strength toward the grand goal of a "Healthy China."